High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial

被引:450
|
作者
Martineau, Adrian R. [1 ,4 ]
Timms, Peter M. [5 ]
Bothamley, Graham H. [5 ]
Hanifa, Yasmeen [1 ]
Islam, Kamrul [1 ]
Claxton, Alleyna P. [5 ]
Packe, Geoffrey E. [6 ]
Moore-Gillon, John C. [7 ,8 ]
Darmalingam, Mathina [9 ]
Davidson, Robert N. [10 ]
Milburn, Heather J. [11 ]
Baker, Lucy V. [12 ]
Barker, Richard D. [13 ]
Woodward, Nicholas J. [14 ]
Venton, Timothy R. [5 ]
Barnes, Korina E. [5 ]
Mullett, Christopher J. [5 ]
Coussens, Anna K. [4 ]
Rutterford, Clare M. [1 ]
Mein, Charles A. [3 ]
Davies, Geraint R. [15 ]
Wilkinson, Robert J. [4 ]
Nikolayevskyy, Vladyslav [2 ]
Drobniewski, Francis A. [2 ]
Eldridge, Sandra M. [1 ]
Griffiths, Christopher J. [1 ]
机构
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, London E1 2AT, England
[2] Barts & London Queen Marys Sch Med & Dent, HPA Natl Mycobacterium Reference Lab, London, England
[3] Barts & London Queen Marys Sch Med & Dent, Genome Ctr, London, England
[4] Natl Inst Med Res, Div Mycobacterial Res, London NW7 1AA, England
[5] Homerton Univ NHS Fdn Trust, London, England
[6] Newham Chest Clin, London, England
[7] St Bartholomews Hosp, Dept Resp Med, London, England
[8] Royal London Hosp, Dept Resp Med, London E1 1BB, England
[9] Whipps Cross Univ Hosp, Dept Resp Med, London, England
[10] Northwick Pk Hosp & Clin Res Ctr, TB Clin, Harrow HA1 3UJ, Middx, England
[11] Guys & St Thomas NHS Fdn Trust, Dept Resp Med, London, England
[12] Lewisham Hosp, Dept Resp Med, London, England
[13] Kings Coll London, Dept Resp Med, London WC2R 2LS, England
[14] Royal Free Hosp, Dept Radiol, London NW3 2QG, England
[15] Univ Liverpool, Sch Clin Sci, Liverpool L69 3BX, Merseyside, England
来源
LANCET | 2011年 / 377卷 / 9761期
关键词
MESSENGER-RNA STABILITY; MYCOBACTERIUM-TUBERCULOSIS; CLINICAL-TRIAL; POLYMORPHISMS; CATHELICIDIN; RIFAMPICIN; SURVIVAL; OUTCOMES; DENSITY;
D O I
10.1016/S0140-6736(10)61889-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Vitamin D was used to treat tuberculosis in the pre-antibiotic era, and its metabolites induce antimycobacterial immunity in vitro. Clinical trials investigating the effect of adjunctive vitamin D on sputum culture conversion are absent. Methods We undertook a multicentre randomised controlled trial of adjunctive vitamin D in adults with sputum smear-positive pulmonary tuberculosis in London, UK. 146 patients were allocated to receive 2.5 mg vitamin D-3 or placebo at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment. The primary endpoint was time from initiation of antimicrobial treatment to sputum culture conversion. Patients were genotyped for TaqI and FokI polymorphisms of the vitamin D receptor, and interaction analyses were done to assess the influence of the vitamin D receptor genotype on response to vitamin D3. This trial is registered with ClinicalTrials.gov number NCT00419068. Findings 126 patients were included in the primary efficacy analysis (62 assigned to intervention, 64 assigned to placebo). Median time to sputum culture conversion was 36.0 days in the intervention group and 43.5 days in the placebo group (adjusted hazard ratio 1.39, 95% CI 0.90-2.16; p=0.14). TaqI genotype modified the effect of vitamin D supplementation on time to sputum culture conversion (p(interaction)=0.03), with enhanced response seen only in patients with the tt genotype (8.09, 95% CI 1.36-48.01; p=0.02). FokI genotype did not modify the effect of vitamin D supplementation (p(interaction)=0.85). Mean serum 25-hydroxyvitamin D concentration at 56 days was 101.4 nmol/L in the intervention group and 22.8 nmol/L in the placebo group (95% CI for difference 68.6-88.2; p<0.0001). Interpretation Administration of four doses of 2.5 mg vitamin D3 increased serum 25-hydroxyvitamin D concentrations in patients receiving intensive-phase treatment for pulmonary tuberculosis. Vitamin D did not significantly affect time to sputum culture conversion in the whole study population, but it did significantly hasten sputum culture conversion in participants with the tt genotype of the TaqI vitamin D receptor polymorphism.
引用
收藏
页码:242 / 250
页数:9
相关论文
共 50 条
  • [41] Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study
    Jorgensen, S. P.
    Agnholt, J.
    Glerup, H.
    Lyhne, S.
    Villadsen, G. E.
    Hvas, C. L.
    Bartels, L. E.
    Kelsen, J.
    Christensen, L. A.
    Dahlerup, J. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (03) : 377 - 383
  • [42] High-Dose Vitamin D3 Administration Is Associated With Increases in Hemoglobin Concentrations in Mechanically Ventilated Critically Ill Adults: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial
    Smith, Ellen M.
    Jones, Jennifer L.
    Han, Jenny E.
    Alvarez, Jessica A.
    Sloan, John H.
    Konrad, Robert J.
    Zughaier, Susu M.
    Martin, Greg S.
    Ziegler, Thomas R.
    Tangpricha, Vin
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2018, 42 (01) : 87 - 93
  • [43] Single High-Dose Vitamin D Supplementation as an Approach for Reducing Ultramarathon-Induced Inflammation: A Double-Blind Randomized Controlled Trial
    Mieszkowski, Jan
    Borkowska, Andzelika
    Stankiewicz, Blaiej
    Kochanowicz, Andrzej
    Niespodzinski, Bartlomiej
    Surmiak, Marcin
    Waldzinski, Tomasz
    Rola, Rafal
    Petr, Miroslav
    Antosiewicz, Jedrzej
    NUTRIENTS, 2021, 13 (04)
  • [44] Effects of vitamin D3 supplementation on cognition and blood lipids: a 12-month randomised, double-blind, placebo-controlled trial
    Hu, Jing
    Jia, Jingya
    Zhang, Yanping
    Miao, Rujuan
    Huo, Xiaoxu
    Ma, Fei
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (12): : 1341 - 1347
  • [45] Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study
    Shaheen, N. J.
    Crockett, S. D.
    Bright, S. D.
    Madanick, R. D.
    Buckmire, R.
    Couch, M.
    Dellon, E. S.
    Galanko, J. A.
    Sharpless, G.
    Morgan, D. R.
    Spacek, M. B.
    Heidt-Davis, P.
    Henke, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (02) : 225 - 234
  • [46] Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study
    Karin Amrein
    Harald Sourij
    Gerit Wagner
    Alexander Holl
    Thomas R Pieber
    Karl Heinz Smolle
    Tatjana Stojakovic
    Christian Schnedl
    Harald Dobnig
    Critical Care, 15
  • [47] Effects of vitamin D3 supplementation on the recovery of hospitalized burn patients: a randomized double-blind controlled trial
    Ghadimi, Elahe
    Rahbar, Roozbeh
    Jafarzade, Elham
    Mansoori, Anahita
    BMC NUTRITION, 2025, 11 (01)
  • [48] Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study
    Amrein, Karin
    Sourij, Harald
    Wagner, Gerit
    Holl, Alexander
    Pieber, Thomas R.
    Smolle, Karl Heinz
    Stojakovic, Tatjana
    Schnedl, Christian
    Dobnig, Harald
    CRITICAL CARE, 2011, 15 (02):
  • [49] A DOUBLE-BLIND CONTROLLED TRIAL OF HIGH-DOSE METHYL PREDNISOLONE IN MULTIPLE-SCLEROSIS
    CARTIER, L
    VERDUGO, R
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1988, 51 (02): : 316 - 316
  • [50] High Dose Vitamin D on Interleukin-10 in Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial.
    FereshtehAshtari
    Nafisehtoghianifar
    SayyedhamidZarkesh-Esfahani
    MarjanMansourian
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 423 - 424